<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1624614</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2025.1624614</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Zebrafish: bona fide pathophysiological models of human diseases</article-title>
<alt-title alt-title-type="left-running-head">Facchinello et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2025.1624614">10.3389/fcell.2025.1624614</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Facchinello</surname>
<given-names>Nicola</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1143097/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Williams</surname>
<given-names>Antionette L.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1168241/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tiso</surname>
<given-names>Natascia</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/121098/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Departments of Pharmacy and Biotechnology</institution>, <institution>University of Bologna</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>IRCCS Istituto delle Scienze Neurologiche di Bologna</institution>, <institution>Programma di Neurogenetica</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Neuroscience Institute</institution>, <institution>Italian Research Council (CNR)</institution>, <addr-line>Padova</addr-line>, <country>Italy</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Division of Ophthalmology</institution>, <institution>Ann and Robert H. Lurie Children&#x2019;s Hospital of Chicago</institution>, <addr-line>Chicago</addr-line>, <addr-line>IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Ophthalmology</institution>, <institution>Northwestern University Feinberg School of Medicine</institution>, <addr-line>Chicago</addr-line>, <addr-line>IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Biology</institution>, <institution>University of Padova</institution>, <addr-line>Padua</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/163095/overview">James Alan Marrs</ext-link>, Indiana University&#x2013;Purdue University Indianapolis, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2316022/overview">Muthukumar Karuppasamy</ext-link>, University of Alabama at Birmingham, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Nicola Facchinello, <email>nicola.facchinello@unibo.it</email>; Antionette L. Williams, <email>anwilliams@luriechildrens.org</email>; Natascia Tiso, <email>natascia.tiso@unipd.it</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1624614</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Facchinello, Williams and Tiso.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Facchinello, Williams and Tiso</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Cell Dev. Biol." xlink:href="https://www.frontiersin.org/research-topics/53997" ext-link-type="uri">Editorial on the Research Topic <article-title>Zebrafish: bona fide pathophysiological models of human diseases</article-title>
</related-article>
<kwd-group>
<kwd>zebrafish</kwd>
<kwd>
<italic>danio rerio</italic>
</kwd>
<kwd>model</kwd>
<kwd>mutant</kwd>
<kwd>human disease</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Molecular and Cellular Pathology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The zebrafish (<italic>Danio rerio</italic>) has emerged as a pivotal vertebrate model in biomedical research, occupying a unique position at the intersection of developmental biology, disease modeling, and translational medicine. With remarkable genetic conservation, optical transparency, rapid embryonic development, and a rich repertoire of genetic tools, zebrafish are now extensively employed to unravel the molecular and cellular mechanisms underlying a broad range of human diseases. This Research Topic gathers a compelling set of eight studies that illustrate the versatility and power of zebrafish in modeling human pathophysiology across diverse organ systems (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Zebrafish as Bona Fide Pathophysiological Models of Human Diseases. The figure summarizes examples of human diseases modeled in zebrafish. The references correspond to the contributions included in the current Research Topic as discussed in this Editorial. The figure was created with <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p>
</caption>
<graphic xlink:href="fcell-13-1624614-g001.tif">
<alt-text content-type="machine-generated">Diagram illustrating zebrafish models for human diseases. Categories include genetic and developmental disorders, neurological disorders, craniofacial disorders, cardiovascular research, and metabolic diseases. Each category lists related research studies with author names and publication years. A central zebrafish image connects to each category, highlighting its role in studying these disorders.</alt-text>
</graphic>
</fig>
<p>Neurodevelopmental and neurodegenerative diseases are well represented in this Research Topic. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2023.1275414">Guzelkaya et al.</ext-link> present a zebrafish model of neonatal hyperbilirubinemia to investigate bilirubin-induced neurological dysfunction (BIND), a condition still poorly understood in human neonates. Their study shows that bilirubin exposure impairs zebrafish locomotion and brain morphology, providing a vertebrate platform for dissecting bilirubin toxicity and testing neuroprotective interventions (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2023.1275414">Guzelkaya et al.</ext-link>).</p>
<p>In a related exploration of nervous system pathology, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1478013">Nies et al.</ext-link> employ a rotenone-induced Parkinson&#x2019;s disease model in zebrafish to assess the therapeutic potential of human metallothionein II (hMT2). Their findings reveal that hMT2 not only mitigates dopaminergic neurodegeneration and oxidative stress but also restores locomotor function, highlighting zebrafish as a translational platform for screening neuroprotective compounds (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1478013">Nies et al.</ext-link>).</p>
<p>The vertebrate cardiac system is another focal point addressed in this Research Topic. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1339292">Angom et al.</ext-link> use a forward genetic screen with gene-breaking trap lines to uncover <italic>grin2bbART</italic>, a novel long non-coding RNA that regulates calcium handling in the zebrafish heart. This study underscores the capacity of zebrafish as a model for uncovering regulators of heart physiology that might otherwise remain elusive in mammalian systems (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1339292">Angom et al.</ext-link>). In a related study, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1384423">Apol&#xed;nov&#xe1; et al.</ext-link> present <italic>ZebraReg</italic>, an innovative automated platform that leverages the innate ability of zebrafish to regenerate heart tissue after injury. This tool allows for high-throughput screening of genes and compounds that influence cardiac regeneration, with clear translational implications for regenerative medicine in humans (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1339292">Angom et al.</ext-link>).</p>
<p>In the domain of metabolic disease, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1381362">Zeng et al.</ext-link> investigate <italic>cobll1a</italic>, a gene encoding a putative cytoskeletal protein involved in lipid metabolism. Their work shows that <italic>cobll1a</italic>-deficient zebrafish exhibit hepatic lipid accumulation due to disrupted retinoic acid signaling, linking this pathway to metabolic disorders, such as fatty liver disease and obesity. These findings reinforce the relevance of zebrafish for modeling and delineating the pathophysiological origins of complex metabolic syndromes (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1381362">Zeng et al.</ext-link>).</p>
<p>Zebrafish also continue to provide crucial insights into developmental genetics and organogenesis. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1496244">Ercanbrack et al.</ext-link> study the effects of <italic>frataxin</italic> knockdown in zebrafish embryos, modeling Friedreich&#x2019;s Ataxia&#x2014;a neurodegenerative disorder with mitochondrial dysfunction. These authors report defects in pronephros (early kidney) formation and embryonic development, expanding our understanding of the systemic roles of <italic>frataxin</italic> and its links to renal phenotypes in human disease (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1496244">Ercanbrack et al.</ext-link>).</p>
<p>Zebrafish are immensely useful and popular genetic models for studying craniofacial development. In the present Research Topic, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1338070">Fox and Waskiewicz</ext-link> review the contributions of zebrafish to understanding the roles of TGF-&#x3b2; and BMP signaling pathways in craniofacial morphogenesis. These authors highlight how zebrafish models replicate key features of congenital anomalies, such as cleft palate and craniosynostosis, offering a tractable system to study gene-environment interactions that influence facial structure (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1338070">Fox and Waskiewicz</ext-link>).</p>
<p>Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2025.1552988">Rossen et al.</ext-link> offer a comprehensive review of how zebrafish are used to model congenital cataracts, particularly those involving crystallin gene mutations. Given the high degree of conservation in lens development between zebrafish and humans, these models allow for real-time imaging of lens transparency and the testing of gene variants implicated in pediatric vision loss. This study highlights the zebrafish as a valuable model for both basic ocular research and therapeutic screening (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2025.1552988">Rossen et al.</ext-link>).</p>
<p>Together, these contributions exemplify the breadth and depth of zebrafish disease modeling. Across these studies, a variety of methodological approaches are employed, including CRISPR-based gene editing, morpholino knockdowns, transgenic reporters, forward genetic screens, and high-throughput imaging and behavioral assays. These tools enable fine-scale dissection of cellular and molecular processes <italic>in vivo</italic> and at scale&#x2014;an asset particularly valuable for preclinical discovery pipelines.</p>
<p>Importantly, several studies in this Research Topic employ advancements beyond modeling toward therapeutic exploration. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1478013">Nies et al.</ext-link> demonstrate the efficacy of hMT2 in ameliorating Parkinsonian phenotypes (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1478013">Nies et al.</ext-link>), while <italic>ZebraReg</italic> offers a pipeline for regenerative compound discovery (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1384423">Apol&#xed;nov&#xe1; et al.</ext-link>). Such efforts underscore the translational potential of zebrafish not just as disease models but also as platforms for therapeutic innovation.</p>
<p>This Research Topic of studies also reflects the ability of zebrafish modeling to integrate systems-level insights. For example, links between developmental signaling and metabolic disease (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1381362">Zeng et al.</ext-link>), or mitochondrial dysfunction and renal development (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1496244">Ercanbrack et al.</ext-link>), illustrate the capacity of zebrafish models to reveal inter-organ and cross-pathway relationships that mirror human physiology and pathology.</p>
<p>Altogether, these studies affirm the zebrafish as a <italic>bona fide</italic> model of human disease, revealing the application of these animals in elucidating disease mechanisms, uncovering new gene functions, and screening therapeutics for a multitude of diseases ranging from monogenic conditions to complex multifactorial disorders. As research advances toward more patient-specific and systems-based approaches, zebrafish remain a cornerstone of translational research, bridging molecular discoveries to practical applications for the prevention of diseases and improvement of human health outcomes.</p>
</body>
<back>
<sec sec-type="author-contributions" id="s1">
<title>Author contributions</title>
<p>NF: Writing &#x2013; review and editing, Writing &#x2013; original draft. AW: Writing &#x2013; original draft, Writing &#x2013; review and editing. NT: Writing &#x2013; review and editing, Writing &#x2013; original draft.</p>
</sec>
<sec sec-type="funding-information" id="s2">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s3">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="ai-statement" id="s4">
<title>Generative AI statement</title>
<p>The author(s) declare that Generative AI was used in the creation of this manuscript. AI was used for grammar check of the text.</p>
</sec>
<sec sec-type="disclaimer" id="s5">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>